Puma Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
Puma Biotechnology's Q3 2024 earnings call on Nov 7, 2024, featured CEO Alan Auerbach, CFO Maximo Nougues, and CCO Jeff Ludwig. The call discussed financial results, with a Q&A session following the formal remarks. The webcast and presentation slides are available on the company's website for 90 days.
Third Quarter 2024 Q3-2024 Commercial Slides
Puma Biotechnology reports $56.1M net NERLYNX revenue in Q3'24, a ~9% increase from Q3'23 and ~26% from Q2'24. 2,723 ex-factory bottles sold, a ~5% decline from Q3'23 but an ~8% increase from Q2'24. ~65% of patients started at a reduced dose. Forward-looking statements involve risks, including COVID-19 impact and regulatory filings.
Puma Biotechnology Reports Third Quarter 2024 Financial Results
Puma Biotechnology reports Q3 2024 net product revenue of $56.1 million, up from $51.6 million in 2023. Total revenue increased to $80.5 million, with net income at $20.3 million. The company focuses on clinical development of alisertib and expects Q4 net product revenue between $46 million and $48 million, revising full-year forecast to $187 million to $190 million.
Puma Biotechnology Reports Inducement Awards
Puma Biotechnology granted a non-executive employee 5,625 restricted stock units, vesting over three years under the 2017 Employment Inducement Incentive Award Plan.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted a 5,625-share restricted stock unit award to a new non-executive employee on Nov 4, 2024, under its 2017 Employment Inducement Incentive Award Plan, vesting over three years.
© Copyright 2024. All Rights Reserved by MedPath